Download PDF
Thromb Haemost 1997; 77(02): 303-307
DOI: 10.1055/s-0038-1655958
Original Article
Schattauer GmbH Stuttgart

Differential Effects of Reconstituted High-density Lipoprotein on Coagulation, Fibrinolysis and Platelet Activation during Human Endotoxemia

Dasja Pajkrt
1   Laboratory of Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Peter G Lerch
2   ZLB Central Laboratory, Blood Transfusion Service SRC, Bern, Switzerland
,
Tom van der Poll
1   Laboratory of Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Marcel Levi
3   Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Marlies Illi
2   ZLB Central Laboratory, Blood Transfusion Service SRC, Bern, Switzerland
,
Jan E Doran
2   ZLB Central Laboratory, Blood Transfusion Service SRC, Bern, Switzerland
,
Beat Arnet
2   ZLB Central Laboratory, Blood Transfusion Service SRC, Bern, Switzerland
,
Abraham van den Ende
3   Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Jan Wouter ten Cate
3   Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Sander J H van Deventer
1   Laboratory of Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 05 July 1996

Accepted after revision 22 October 1996

Publication Date:
10 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

High-density lipoproteins (HDL) can bind and neutralize lipopoly- saccharides (LPS) in vitro and in vivo. HDL can also affect fibrinolytic activity and can directly influence platelet function by reducing platelet aggregation. In this study, the effects of reconstituted HDL (rHDL) on LPS-induced coagulation, fibrinolysis and platelet activation in humans were investigated. In a double-blind, randomized, placebo-controlled, cross-over study, eight healthy male volunteers were injected with LPS (4 ng/kg) on two occasions, once in conjunction with rHDL (40 mg/kg, given as a 4 h infusion starting 3.5 h prior to LPS injection), and once in conjunction with placebo. rHDL significantly reduced LPS-induced activation of coagulation (plasma levels of prothrombin fragment F1+2) and fibrinolysis (plasma levels of tissue type plasminogen activator antigen, t-PA). No effect was observed on LPS-induced inhibition of the fibrinolytic pathway (PAI-1) or on the transient thrombocytopenia elicited by LPS. Furthermore, rHDL treatment significantly enhanced the inhibition of collagen-stimulated inhibition of platelet aggregation during endotoxemia, but had no such effect on arachido- nate-stimulated platelet aggregation. rHDL treatment per se also reduced collagen-induced platelet aggregation. These results indicate that rHDL modifies the procoagulant state associated with endotoxemia.

 

  • References

  • 1 Gawaz M, Fateh-Moghadam S, Pilz G, Gurland HJ, Werdan K. Platelet activation and interaction with leucocytes in patients with sepsis and multiple organ failure. Eur J Clin Invest 1995; 25: 843-851
    CrossrefPubMedGoogle Scholar
  • 2 Levi M, ten Cate H, van der PollT, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979
    CrossrefPubMedGoogle Scholar
  • 3 ten Cate H, Brandjes DPM, Wolters HJ, van DeventerSJH. Disseminated intravascular coagulation: pathophysiology, diagnosis, and treatment. New Horizons 1993; 01: 312-323
    PubMedGoogle Scholar
  • 4 Emancipator K, Csako G, Elin RJ. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992; 60: 596-601
    PubMedGoogle Scholar
  • 5 Suffredini AF, Harpel PC, Parillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-1172
    CrossrefPubMedGoogle Scholar
  • 6 Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation fibrinolytic, and complement pathways. Blood 1990; 76: 252-256
    PubMedGoogle Scholar
  • 7 Csako G, Suba EA, Elin RJ. Endotoxin-induced platelet activation in human whole blood in vitro. Thromb Haemost 1998; 59: 378-382
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Stuart MJ. Effect of endotoxin on arachidonic acid release and thromboxane B2 production by human platelets. Am J Hematol 1981; 11: 159-164
    CrossrefPubMedGoogle Scholar
  • 9 Gralnick HR, Elin R, Abrans E, Givelber H, Wolff SM. Effects of endotoxin (LPS) on blood coagulation in humans. Clin Res 1976; 24: 344A
    PubMedGoogle Scholar
  • 10 Cohen P, Braunwald J, Gradner FH. Destruction of canine platelets and rabbit platelets following intravenous administration of carbon particles or endotoxin. J Clin Lab Med 1965; 66: 263-271
    PubMedGoogle Scholar
  • 11 Fletcher JG, Ramwell PW. The effects of prostacyclin (PGI2) on endotoxic shock and endotoxin-induced platelet aggregation in dogs. Circ Shock 1980; 07: 299-308
    PubMedGoogle Scholar
  • 12 Spielvogel AR. An ultrastructural study of the mechanisms of platelet-endotoxin interaction. J Exp Med 1967; 126: 235-250
    CrossrefPubMedGoogle Scholar
  • 13 Flegel WA, Wӧlpl A, Mӓnnel DA, Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57: 2237-2245
    PubMedGoogle Scholar
  • 14 Baumberger C, Ulevitch RJ, Dayer JM. Modulation of endotoxin activity of lipopolysaccharide by high-density lipoprotein. Pathobiology 1991; 59: 378-383
    CrossrefPubMedGoogle Scholar
  • 15 Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low-and high-density lipoproteins and by apolipoprotein A-l. Infect Immun 1993; 61: 5140-5146
    PubMedGoogle Scholar
  • 16 Levine DM, Parker TS, Donelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90: 12040-12044
    CrossrefPubMedGoogle Scholar
  • 17 Parker TS, Levine DM, Chuang JCC, Laxer J, Coffin CC, Rubin AL. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lippolysaccharides in human whole blood. Infect Immun 1995; 63: 253-258
    PubMedGoogle Scholar
  • 18 Hubsch AP, Powell FS, Lerch PG, Doran JE. A reconstituted apolipoprotein A-l containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circulatory Shock 1993; 40: 14-23
    PubMedGoogle Scholar
  • 19 Cue JI, Di Piro JT, Brunner LJ, Doran JE, Blankenship ME, Mansberger AR, Hawkins ML. Reconstituted high-density lipoprotein inhibits physiologic and tumor necrosis factor a responses to lipopolysaccharide in rabbits. Arch Surg 1994; 129: 193-197
    CrossrefPubMedGoogle Scholar
  • 20 Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C. Role of circulating lipoproteins in protection from endotoxin activity. Infect Immun 1995; 63: 2041-2046
    PubMedGoogle Scholar
  • 21 Malyszko J, Urano T, Knofler R, Ihara H, Takada Y, Takada A. Relationships between serum lipids serotonin, platelet aggregation and some fibrinolysis parameters in humans. Life Science 1994; 55: 1619-1623
    CrossrefPubMedGoogle Scholar
  • 22 Koller E, Koller F, Doleschel W. Specific binding sites on human platelets for plasma lipoproteins. Hoppe-Seyler’s Z Physiol Chem 1982; 363: 395-405
    PubMedGoogle Scholar
  • 23 Koller E, Koller F, Binder BR. Purification and identification of the lipoprotein-binding proteins from human blood platelet membrane. J Biol Chem 1989; 264: 12412-12418
    PubMedGoogle Scholar
  • 24 Malle E, Sattler W. Platelets and lipoproteins: native, modified and platelet modified lipoproteins. Platelets 1994; 05: 70-83
    CrossrefPubMedGoogle Scholar
  • 25 Surya II, Akkerman JWN. The influence of lipoproteins on blood platelets. Am Heart J 1993; 125: 272-275
    CrossrefPubMedGoogle Scholar
  • 26 Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der PollT, ten Cate JW, van Deventer SJH. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 180: 1601-1608
    PubMedGoogle Scholar
  • 27 Lerch PG, Fortsch V, Hodler G, Bolli R. Production and characterization of a reconstituted high density lipoprotein (rHDL) for therapeutic applications. Vox Sang 1996; 71: 155-164
    CrossrefPubMedGoogle Scholar
  • 28 Von der MӧhlenMAM, Kimmings AN, Wedel NI, Mevissen MLCM, Jansen J, Friedmann N, Lorenz TJ, Nelson BJ, White ML, Bauer R, Hack CE, Eerenberg A, van Deventer SJH. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans using recombinant bactericidal/permeability-increasing protein (rBPI23). J Infect Dis 1995; 172: 144-151
    CrossrefPubMedGoogle Scholar
  • 29 Van derPoll T, Levi M, Hack CE, van Deventer SJH, ten Cate H, Haagmans B, Biemond BJH, Büller HR, ten Cate JW. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994; 83: 446-451
    PubMedGoogle Scholar
  • 30 Van derPoll T, Levi M, Hack CE, ten Cate H, van Deventer SJH, Eerenberg AJM, de Groot ER, Jansen J, Gallati H, Büller HR, ten Cate JW, Aarden LA. Elimination of Interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-1259
    CrossrefPubMedGoogle Scholar
  • 31 Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apoliporoteins of high denity lipoproteins in man. Thromb Res 1985; 39: 01-08
    CrossrefPubMedGoogle Scholar
  • 32 Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantha-ramaiah GM. HDL and Apolipoprotein A-l protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 1994; 14: 1775-1783
    CrossrefPubMedGoogle Scholar
  • 33 Waysbort J, Schwartz S, Brunner D. Effect of bezafibrate on lipids lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients. Arzneim Forsch 1994; 44: 1217-1222
    PubMedGoogle Scholar
  • 34 Sermet A, Aybak M, Ulak G, Guzel C, Denli O. Effect of oral pyridoxine hydrochloride supplementation on in vitro platelet sensitivity to different agents. Arzneim Forsch 1995; 45: 19-21
    PubMedGoogle Scholar
  • 35 Higashihara M, Kinoshita M, Teramoto T, Kume S, Kurokawa K. The role of ApoE in inhibitory effects of apoE-rich HDL on platelet function. FEBS 1991; 282: 82-86
    CrossrefPubMedGoogle Scholar
  • 36 Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-l (apoA-1). J Clin Invest 1988; 82: 803-807
    CrossrefPubMedGoogle Scholar
  • 37 Radomski MW, Palmer RMJ, Moncada S. Characterization of the L-argi-nine: nitic oxide pathway in human platelets. Br J Heamatol 1990; 101: 325-328
    PubMedGoogle Scholar
  • 38 Chen LY, Mehta JL. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Science 1994; 55: 1815-1821
    CrossrefPubMedGoogle Scholar
  • 39 Satoh K, Imaizumi TA, Yoshida H, Takamatsu S. High-density lipoprotein inhibits the production of platelet activating factor acetylhydrolase by HepG2 cells. J Clin Lab Med 1994; 124: 225-231
    PubMedGoogle Scholar
  • 40 Sugatani J, Miwa M, Komiyama Y, Ito S. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal 1996; 13: 73-88
    CrossrefPubMedGoogle Scholar
  • 41 Surya II, Gorter G, Akkerman JW. Arachidonate transfer between platelets and lipoproteins. Thromb Haemost 1992; 68: 719-726
    Article in Thieme ConnectPubMedGoogle Scholar